The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
A study of 95,559 UK Biobank participants links estimated sleep stages and duration to subsequent diagnoses. The observational findings do not establish that changing a sleep-stage score prevents illness.
University researchers are recruiting women ages 50–75 to evaluate a remote exercise and nutrition program. The study will examine feasibility and sarcopenia-related outcomes; clinical benefits remain unestablished.
September 17 conference materials put the investigational GIP/GLP-1 drug’s psychiatric program in focus. The studies test clinical outcomes beyond weight management, but their designs do not establish treatment benefit.
A new framework draws on mouse research to identify biological signals that might help prioritize longevity interventions. The proposed markers still need validation before they can establish treatment benefits in people.
The pharmaceutical supplier plans to expand peptide ingredients and technical services. The announcement follows an FDA alert involving a separate supplement-grade ingredient supplied by the company, underscoring the importance of intended use and manufacturing controls.
The new indication follows a trial showing reduced urinary albumin over six months. The labeling describes longer-term kidney protection as an expected benefit, preserving an important distinction between a biomarker result and clinical outcomes.
A new study tests separate biological-aging models for females and males across organ systems. The findings raise questions about how aging scores should be interpreted in prevention research.
An initial 19-patient update describes safety and drug-exposure observations from the FOCUS-01 trial. Whether the investigational treatment improves cancer outcomes remains unresolved.
The program pairs drug developers with research institutions and introduces rolling review before a complete trial application. Whether it shortens development while preserving participant protection remains to be demonstrated.
Researchers found associations between healthier dietary patterns and more favorable molecular aging measures. The observational study does not establish that changing diets slows aging or extends life.
The investigational oral drug produced sponsor-reported weight loss in a 12-week trial. Longer studies and direct comparisons are needed to assess its safety and potential place alongside established obesity treatments.
The initiative will develop computational models of hormone regulation across the lifespan. Its relevance to healthy aging lies in improving research on treatment response and toxicity, with clinical benefits still untested.